Of clinical relevance, the group of patients without CN alterations trended toward an inferior progression-free survival (P=0.098, Figure 6B), which was previously observed in a cohort of systemic ALK+ALCL not strictly pediatric 26. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.